Paper40057791
Bridging epigenomics and tumor immunometabolism: molecular mechanisms and therapeutic implications.
Xie X and 4 others. Mol Cancer, 2025. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Bridging epigenomics and tumor immunometabolism: molecular mechanisms and therapeutic implications. Papers, record 40057791. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40057791
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Bridging epigenomics and tumor immunometabolism: molecular mechanisms and therapeutic implications.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Epigenomics | Major topic |
| Epigenesis, Genetic | Major topic |
| Humans | |
| Tumor Microenvironment | |
| Animals | |
| Immunotherapy | |
| DNA Methylation | |
| Gene Expression Regulation, Neoplastic |
Source PubMed
References209
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37757492 | Reprogramming the lipid metabolism of dendritic cells in tumor immunomodulation and immunotherapy. | Biomed Pharmacother | 2023 | https://conductscience.org/library/papers/37757492 | PubMed |
| 2 | 33546704 | The cancer metabolic reprogramming and immune response. | Mol Cancer | 2021 | https://conductscience.org/library/papers/33546704 | PubMed |
| 3 | 35340204 | Histone Methylation and Oxidative Stress in Cardiovascular Diseases. | Oxid Med Cell Longev | 2022 | https://conductscience.org/library/papers/35340204 | PubMed |
| 4 | 35316657 | The glucose transporter GLUT3 controls T helper 17 cell responses through glycolytic-epigenetic reprogramming. | Cell Metab | 2022 | https://conductscience.org/library/papers/35316657 | PubMed |
| 5 | 31475443 | Functions and mechanisms of lysine crotonylation. | J Cell Mol Med | 2019 | https://conductscience.org/library/papers/31475443 | PubMed |
| 6 | 35836809 | Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents. | Theranostics | 2022 | https://conductscience.org/library/papers/35836809 | PubMed |
| 7 | 35292092 | LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond. | J Exp Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35292092 | PubMed |
| 8 | 36323249 | Metabolic regulation by p53 prevents R-loop-associated genomic instability. | Cell Rep | 2022 | https://conductscience.org/library/papers/36323249 | PubMed |
| 9 | 37801083 | BCAT2 promotes melanoma progression by activating lipogenesis via the epigenetic regulation of FASN and ACLY expressions. | Cell Mol Life Sci | 2023 | https://conductscience.org/library/papers/37801083 | PubMed |
| 10 | 33953707 | Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment. | Front Immunol | 2021 | https://conductscience.org/library/papers/33953707 | PubMed |
| 11 | 33581341 | Profiling Chromatin Accessibility at Single-cell Resolution. | Genomics Proteomics Bioinformatics | 2021 | https://conductscience.org/library/papers/33581341 | PubMed |
| 12 | 38829740 | The histone deacetylase HDAC1 controls dendritic cell development and anti-tumor immunity. | Cell Rep | 2024 | https://conductscience.org/library/papers/38829740 | PubMed |
| 13 | 31097476 | HDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac/H3K9me3 Transition. | Cancer Res | 2019 | https://conductscience.org/library/papers/31097476 | PubMed |
| 14 | 35389425 | Metaboloepigenetics in cancer, immunity, and cardiovascular disease. | Cardiovasc Res | 2023 | https://conductscience.org/library/papers/35389425 | PubMed |
| 15 | 32795401 | Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. | Cancer Cell | 2020 | https://conductscience.org/library/papers/32795401 | PubMed |
| 16 | 30293904 | Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. | Eur Urol | 2019 | https://conductscience.org/library/papers/30293904 | PubMed |
| 17 | 34330764 | Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/34330764 | PubMed |
| 18 | 31830561 | ATP citrate lyase: A central metabolic enzyme in cancer. | Cancer Lett | 2020 | https://conductscience.org/library/papers/31830561 | PubMed |
| 19 | 33301708 | Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. | Cell | 2020 | https://conductscience.org/library/papers/33301708 | PubMed |
| 20 | 39251875 | Spatial single-cell isotope tracing reveals heterogeneity of de novo fatty acid synthesis in cancer. | Nat Metab | 2024 | https://conductscience.org/library/papers/39251875 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42903418 | Molecular mechanisms and therapeutic strategies of immunotherapy resistance in esophageal cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42903418 | PubMed |
| 42882485 | The Crosstalk Between Metabolic Reprogramming and Histone Methylation in Tumor Immunity and Immunotherapy. | Cells | 2026 | https://conductscience.org/library/papers/42882485 | PubMed |
| 42724854 | Combined multi-omics profiling and machine learning analysis reveals that Bregs and RPS2 promote bone metastasis in nasopharyngeal carcinoma. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42724854 | PubMed |
| 42405329 | Tumor suppressor network dysregulation in neuroblastoma: molecular mechanisms and precision therapeutic opportunities. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42405329 | PubMed |
| 42393287 | Histone lactylation-driven IGF2BP3 promotes intrahepatic cholangiocarcinoma progression via SPP1/CD44-dependent macrophage polarization. | Oncogene | 2026 | https://conductscience.org/library/papers/42393287 | PubMed |
| 42298579 | The nutrigenomic-epigenetic axis in cancer: from dietary bioactives to precision oncology. | Nutr Metab (Lond) | 2026 | https://conductscience.org/library/papers/42298579 | PubMed |
| 42222599 | Tumor ecosystem subtyping of breast cancer based on somatic mutations and network propagation reveals distinct prognostic and genomic landscapes. | Front Genet | 2026 | https://conductscience.org/library/papers/42222599 | PubMed |
| 42103495 | Bioengineered systems to exploit tumor microenvironment metabolism. | Trends Cancer | 2026 | https://conductscience.org/library/papers/42103495 | PubMed |
| 42100377 | The multistep progression of areca nut-induced oral cancer: a mechanistic roadmap from pathogenesis to precision therapy. | Life Med | 2026 | https://conductscience.org/library/papers/42100377 | PubMed |
| 42043678 | The crosstalk between epigenetics and metabolism in the malignant cell. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42043678 | PubMed |
| 41977178 | Conserved Pathways, Divergent Outcomes: A Cross-Species Genomic Perspective on the Cancer-Neurodegeneration Paradox. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41977178 | PubMed |
| 41814059 | Artificial intelligence-assisted spatial omics-based biomimetic nanoplatform for intelligent and precise intervention in the immunosuppressive core region of ovarian cancer. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/41814059 | PubMed |
| 41663693 | Hepatic stellate cell derived lipid droplets drive protumoral M2 macrophage polarization in hepatocellular carcinoma. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41663693 | PubMed |
| 41311372 | Emerging hallmarks and the rise of complexities and heterogeneity of tumor. | Biochem Biophys Rep | 2025 | https://conductscience.org/library/papers/41311372 | PubMed |
| 41036475 | Delving Into the Dialogue between Epigenetic Modifications and Immunometabolism in Cancer. | Adv Genet (Hoboken) | 2025 | https://conductscience.org/library/papers/41036475 | PubMed |
| 40938975 | Metabolism-driven posttranslational modifications and immune regulation: Emerging targets for immunotherapy. | Sci Adv | 2025 | https://conductscience.org/library/papers/40938975 | PubMed |
| 40808802 | Substituted 1,4-naphthoquinones for potential anticancer therapeutics: In vitro cytotoxic effects and QSAR-guided design of new analogs. | Comput Struct Biotechnol J | 2025 | https://conductscience.org/library/papers/40808802 | PubMed |
| 40358164 | Epigenetic Control of Alveolar Macrophages: Impact on Lung Health and Disease. | Cells | 2025 | https://conductscience.org/library/papers/40358164 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40057791
GET https://conductscience.org/api/papers/v1/40057791/references?page=2